Real-World Data Assessing Heart Failure Outcomes In Patients Implanted With Wireless Pulmonary Pressure Monitoring Device

• Published in: Journal of cardiac failure 2025-01, Vol.31 (1), p.213-214
• Main Authors: Karnkowska, Barbara, Yaqub, Maha, Cuellar, Servando, Malik, Hamza, Alnajjar, Hanan, Truong, Loan, Iturrizaga-Murrieta, Jose, Khan, Fatima, Khalife, Wissam
• Format: Article
• Language: English
• ISSN: 1071-9164
• DOI: 10.1016/j.cardfail.2024.10.087

Multiple studies, including the landmark CHAMPION trial, have demonstrated significant reduction of heart failure (HF) admissions in patients implanted with wireless pressure monitoring device (CardioMEMS). The implant is designed to sense changes in pulmonary arterial pressures which are transmitted to the healthcare providers in real time to help guide HF management. Patient's eligibility for the implant is based on functional capacity assessed using New York Heart Association class (NYHA); those in class II or III are considered for the device. Multiple randomized control trials have shown reduction of hospital readmissions and associated healthcare costs; however, little is known about HF outcomes in patients, status post implant. In this study, we assessed HF outcomes in those implanted with the CardioMEMS device. This is a retrospective chart review of patients with recurrent admissions for HF implanted with the wireless pressure monitoring system (CardioMEMS) between April 2018, and January 2024 at our academic center. We investigated the NYHA classification and ejection fraction (EF) of patients at the time of device implantation and up to 12-month mark. Improvement in EF was defined as an increase of ≥10% from baseline; conversely, reduction of EF was defined as ≤10% decrease. Of the 100 patients who had successfully undergone CardioMEMS implantation at our institution 56% were males. Cohort demographics included average age 69 ±12 years, 55% of patients with nonischemic disease (NICMP), and 45% with HF preserved EF (HFpEF). Overall, 10% of the patients improved in NYHA of ≥ 1 class. Of those who improved, 70% had NICM, and 60% had HF with reduced EF (HFrEF). Worsening of NYHA class from baseline was noted in 6 patients equally distributed between type and etiology of HF. Regarding the LV function, among patients with reduced EF (n=55), the EF improved in 9 patients (16%), in whom 66% had ischemic disease (ICMP). Reduction in EF was recorded in 12 patients (12%) of the total cohort within a 1-year period post implant (5 HFpEF and 7 HFrEF). Those with NICMP were twice as likely to experience an EF reduction (66% vs 33%). Descriptive statistics of real-world data from an academic center suggest that patients with NICMP and HFrEF are more likely to experience improvement in HF symptoms after receiving CardioMEMS implant. However, patients with ICMP are more likely to improve their EF at 12 months post implant. A larger study is needed to assess the e